Inhibrx Biosciences, Inc.
INBXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. At a $1.37B market cap, Inhibrx Biosciences, Inc. ranks as a small-cap company within healthcare. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Market Cap
$1.37B
Beta
3.82
P/E (TTM)
—
P/E (Fwd)
-10.66
EPS (TTM)
$-8.88
EPS (Fwd)
$-8.76
ROE
-1773.6%
ROA
-43.6%
Cash
$133.3M
Total Debt
$181.6M
Free CF
-$85.1M
52W Change
58.7%
Annual Financials
Cash vs Debt
Where INBX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INBX finished 7.14% below its 150-day moving average ($96.69) and 1.97% below its 200-day moving average ($91.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INBX overbought or oversold?
At the October 20, 2026 close, INBX's RSI(14) was 24.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, INBX has $133.3M in cash with $181.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$85.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1773.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $1.3M (2022) to $1.3M (2025).
A beta of 3.82 means INBX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inhibrx Biosciences, Inc.'s trajectory.